New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
04:55 EDTPFE, PFE, PFE, PFE, BMY, BMY, BMY, BMY, NVS, NVS, NVS, NVS, LLY, LLY, LLY, LLYCambridge Healthtech Institute to host a conference
10th Annual High-Content Analysis Conference is being held in San Francisco on January 8-11.
News For PFE;BMY;NVS;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 >>
October 9, 2015
07:01 EDTLLYEli Lilly to add 30,000 square feet in R&D presence in New York
Subscribe for More Information
05:54 EDTLLYEli Lilly upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Vamil Divan upgraded Eli Lilly (LLY) to Outperform after his survey of 51 physicians suggested increasing use of the company's diabetes drug Jardiance. Jardiance is likely to drive near-term upside to Lilly while the company's pipeline is being underappreciated at current share levels, Divan tells investors in a research note. He raised his price target for shares to $105 from $89. The pharmaceutical giant closed yesterday down 24c to $83.75. The analyst also raised his sales estimates for Merck (MRK) and Johnson & Johnson (JNJ) following his physician survey.
October 8, 2015
07:05 EDTLLYEli Lilly's breast cancer candidate receives Breakthrough Therapy Designation
Subscribe for More Information
06:32 EDTBMY, LLY, PFEPiper Jaffray explains why drug prices are justifiable
Piper Jaffray's team of Biopharma analysts, led by Joshua Schimmer, explain this morning in research note to investors why they believe drug prices are justifiable. The "fairly lopsided" drug-pricing discussion "noise" has created attractive entry points for stocks in the sector, the analysts argue. They say that after adjusting for actual inflation, the growth of drug prices "does not seem particularly concerning." The current dialogue on the topic under-emphasizes the need to provide "extremely attractive incentives" for companies to embark on the "highly risky, capital-intensive, long-development cycle drug development path which is needed to bring new cures for important diseases," the analysts contend. Schimmer's top picks are Alexion (ALXN), Celgene (CELG) and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC) and Ignyta (RXDX) in the small-cap sector.
05:27 EDTNVSNovartis reports long-term efficacy of Gilenya
Subscribe for More Information
October 7, 2015
16:50 EDTNVSNovartis' Sandoz Canada launches PrSandoz Solifenacin on Canadian market
Sandoz Canada announced the launch of a new drug on the Canadian market, PrSandoz Solifenacin, which is used in reducing urinary urgency, frequency and incontinence. PrSandoz Solifenacin is a generic equivalent to the product Vesikur marketed in Canada under the name PrVesicare. This generic drug is available immediately on the Canadian market. Sandoz Canada is part of Sandoz International GmbH, the world's second largest producer of generic drugs and a company of the Swiss multinational corporation, Novartis (NVS).
08:04 EDTBMYSeattle Genetics initiates Phase 1/2 trial of ADCETRIS
Seattle Genetics (SGEN) announced that it has initiated a phase 1/2 clinical trial of ADCETRIS in combination with Opdivo for patients with relapsed or refractory Hodgkin lymphoma, or HL, after failure of frontline treatment. The trial is being conducted under a previously announced clinical trial collaboration agreement with Bristol-Myers Squibb (BMY). ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL, which combines the targeting ability of a monoclonal antibody with a highly potent cell-killing agent. Opdivo is a human antibody that targets and inhibits the programmed death receptor-1, resulting in T-cell activation. Opdivo is part of a new class of cancer immunotherapy treatments known as checkpoint inhibitors, which are designed to harness the body's own immune system in fighting cancer by targeting distinct regulatory components of the immune system. A second trial under the collaboration is planned to begin later in 2015 for relapsed or refractory B-cell and T-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma.
07:36 EDTPFE, BMYInfectious Diseases Society of America to hold a conference
Subscribe for More Information
07:34 EDTNVSAlliance for Regenerative Medicine to hold a meeting
Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 7-9.
07:23 EDTNVSEuropean Committee Treatment & Research in Multiple Sclerosis holds meeting
Subscribe for More Information
07:05 EDTPFEPfizer, Merck KGaA say avelumab gets FDA fast track designation
Subscribe for More Information
October 6, 2015
16:12 EDTPFETRACON Pharmaceuticals appoints Ronald Shazer as Chief Medical Officer
Subscribe for More Information
13:32 EDTPFE, BMY, LLY, NVSBiotechs plummet with TPP seen as industry negative
Biotechs are falling intraday after reports that the Trans-Pacific Partnership, or TPP, has language that the exclusivity period for bioligics, or drugs derived from a biological sources, would be eight years, less than the twelve years it is currently in the United States. WHAT'S NOTABLE: In the U.S., biologics are protected from competition by follow-on products for twelve years from the time they are first granted marketing approval by the U.S. Food and Drug Administration, a protection that is distinct from patent protection. Recent reports on the TPP suggest that the protection will last five years with an additional safety monitoring period of up to three years before a biosimilar can be registered, which would effectively be an eight year exclusivity period. ANALYST REACTION: Piper Jaffray analyst Joshua Schimmer, however, said the development is a "step forward," especially since it does not overrule the 12 years' exclusivity for the drugs in the U.S. While the sector asked for twelve years' exclusivity to match the U.S., eight years is a "reasonable compromise," the analyst argued. His top picks were Alexion (ALXN), Celgene (CELG), and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC), and Ignyta (RXDX) in the small-cap sector. Further, Schimmer stated that more names look "increasingly compelling" amid the selloff. NOTABLE DECLINERS: Alexion is lower by 2.53%, Celgene is down 4.32%, Amgen is declining 1.91%, Biogen (BIIB) is down 3.4%, and Gilead Sciences (GILD) is falling 2.22%. STOCKS TO WATCH: Other publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07:23 EDTPFEAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:01 EDTBMYBristol-Myers says granted FDA priority review for Daklinza sNDAs
Subscribe for More Information
05:23 EDTLLYEli Lilly, Adocia initiate Phase 1b study of BioChaperone Lispro
Subscribe for More Information
October 5, 2015
11:09 EDTBMYBristol-Myers to pay $14M to settle SEC charge of FCPA violations
Subscribe for More Information
10:19 EDTPFESpark trial success a positive for gene therapy sector, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he views the news that Spark Therapeutics (ONCE) "highly anticipated" SPK-RPE65 Phase 3 gene therapy study for congenital blindness met its primary endpoint as a positive for the ophthalmology gene therapy field as well as the broader gene therapy sector. Schimmer added that Applied Genetic Technologies' (AGTC) early clinical data in the second half of this year will be a further test of the ophthalmology gene therapy platform. The analyst noted that other companies with gene therapy programs include Avalanche (AAVL), Biogen (BIIB), bluebird bio (BLUE), BioMarin (BMRN), Cellectis (CLLS), Medgenics (MDGN), uniQure (QURE), Pfizer (PFE), Regeneron (REGN) and Sangamo (SGMO).
05:25 EDTNVSAlcon receives FDA approval for AcrySof IQ Aspheric IOL
Subscribe for More Information
October 2, 2015
10:00 EDTPFEOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alexion (ALXN) upgraded to Overweight from Equal Weight at Morgan Stanley... BlackRock (BLK) upgraded to Buy from Neutral at UBS... Dunkin' Brands (DNKN) upgraded to Outperform from Underperform at CLSA... EnPro (NPO) upgraded to Buy from Neutral at Sidoti... Finish Line (FINL) upgraded to Neutral from Sell at Goldman... FutureFuel (FF) upgraded to Buy from Neutral at Roth Capital... Google (GOOG) upgraded to Outperform from Perform at Oppenheimer... Johnson Controls (JCI) upgraded to Buy from Neutral at Nomura... Kennametal (KMT) upgraded to Neutral from Underperform at BofA/Merrill... Lufthansa (DLAKY) upgraded to Buy from Hold at HSBC... Martin Marietta (MLM) upgraded to Buy from Neutral at Longbow... Northern Trust (NTRS) upgraded to Neutral from Sell at UBS... PMC-Sierra (PMCS) upgraded to Positive from Neutral at Susquehanna... Pfizer (PFE) upgraded to Overweight from Equal Weight at Morgan Stanley... Realogy (RLGY) upgraded to Buy from Neutral at Citi... Sarepta (SRPT) upgraded to Outperform from Neutral at Wedbush... Summit Materials (SUM) upgraded to Buy from Neutral at Goldman... TreeHouse (THS) upgraded to Buy from Neutral at BofA/Merrill... Vertex (VRTX) upgraded to Overweight from Equal Weight at Morgan Stanley.
<< 1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use